BRIEF published on 09/24/2024 at 23:05, 2 years ago Theralase clôture un placement privé sans intermédiaire et émet des options sur actions Placement Privé Sans Intermédiaire Technologies Théralase Options Sur Actions Financement De La Recherche Clinique Étude Sur Le Cancer De La Vessie
BRIEF published on 09/24/2024 at 23:05, 2 years ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 2 years ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 2 years ago Theralase® prolonge ses mandats Extension Bourse De Croissance TSX Technologies Théralase Bons De Souscription D'actions Développement Pharmaceutique
BRIEF published on 09/19/2024 at 23:10, 2 years ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 2 years ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 2 years 1 month ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
BRIEF published on 09/03/2024 at 13:05, 2 years 1 month ago Ruvidar(TM) s'avère plus efficace que l'acyclovir dans la destruction du virus de l'herpès simplex Theralase Ruvidar Médicament Antiviral HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 2 years 1 month ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 2 years 1 month ago Rutherrin® augmente l'efficacité de la chimiothérapie contre le cancer du poumon Theralase® Technologies Inc. Chimiothérapie CPNPC Rutherrine® Cisplatine
Published on 10/02/2026 at 13:50, 1 day 14 hours ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 15 hours ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 15 hours ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/03/2026 at 15:45, 12 hours 33 minutes ago Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 1 day 4 hours ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 7 hours ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 8 hours ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 19:00, 1 day 9 hours ago INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 10/02/2026 at 17:45, 1 day 10 hours ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 1 day 10 hours ago Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 1 day 10 hours ago Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 1 day 10 hours ago Aéroports de Paris SA - Calendrier financier 2027
